[1] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015,136(5):359-386.
[2] SAKAMOTO K M, KIM K B, KUMAGAI A, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation[J]. Proc Natl Acad Sci USA, 2001, 98(15):8554-8559.
[3] VEGGIANI G, GERPE M C R, SIDHU S S, et al. Emerging drug development technologies targeting ubiquitination for cancer therapeutics[J]. Pharmacol Ther, 2019, 199:139-154.
[4] SCHAPIRA M, CALABRESE M F, BULLOCK A N, et al. Targeted protein degradation: expanding the toolbox[J]. Nat Rev Drug Discov, 2019, 18(12):949-963.
[5] DANG C V, REDDY E P, SHOKAT K M, et al. Drugging the “undruggable” cancer targets[J]. Nat Rev Cancer, 2017, 17(8):502-508.
[6] ZHOU H, BAI L, XU R, et al. Structure-Based Discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein[J]. J Med Chem, 2019,62(24):11280-11300.
[7] CHESSUM N E A, SHARP S Y, CALDWELL J J, et al. Demonstrating in-cell target engagement using a pirin protein degradation probe (CCT367766)[J]. J Med Chem, 2018, 61(3):918-933.
[8] BASSI Z I, FILLMORE M C, MIAH A H, et al. Modulating PCAF/GCN5 immune cell function through a PROTAC approach[J]. ACS Chem Biol, 2018, 13(10):2862-2867.
[9] BONDESON D P, SMITH B E, BURSLEM G M, et al. Lessons in PROTAC design from selective degradation with a promiscuous warhead[J]. Cell Chem Biol, 2018, 25(1):1-15.
[10] HUANG H T, DOBROVOLSKY D, PAULK J, et al. A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader[J]. Cell Chem Biol, 2018, 25(1):1-12.
[11] BUHIMSCHI A D, ARMSTRONG H A, TOURE M, et al. Targeting the C481S Ibrutinib-resistance mutation in Bruton′s tyrosine kinase using PROTAC-mediated degradation[J]. Biochemistry, 2018, 57(26):3564-3575.
[12] SUN Y, ZHAO X, DING N, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies[J]. Cell Res, 2018, 28(7):779-781.
[13] PETTERSSON M, CREWS C M. PROteolysis targeting chimeras (PROTACs)-past, present and future[J]. Drug Discov Today Technol, 2019, 31:15-27.
[14] SUN X, WANG J, YAO X, et al. A chemical approach for global protein knockdown from mice to non-human primates[J]. Cell Discov, 2019, 5(10):1-13.
[15] LI Y, YANG J, AGUILAR A, et al. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression[J]. J Med Chem, 2019, 62(2):448-466.
[16] LU M, LIU T, JIAO Q, et al. Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway[J]. Eur J Med Chem, 2018, 146:251-259.
[17] SILVA M C, FERGUSON F M, CAI Q, et al. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models[J]. Elife, 2019, 8:e45457.
[18] SCHNEEKLOTH J S J R, FONSECA F N, KOLDOBSKIY M, et al. Chemical genetic control of protein levels: selective in vivo targeted degradation[J]. J Am Chem Soc, 2004, 126(12):3748-3754.
[19] LEE H, PUPPALA D, CHOI E Y, et al. Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool[J]. Chembiochem, 2007, 8(17):2058-2062.
[20] SCHNEEKLOTH A R, PUCHEAULT M, TAE H S, et al. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics[J]. Bioorg Med Chem Lett, 2008, 18(22):5904-5908.
[21] SEKINE K, TAKUBO K, KIKUCHI R, et al. Small molecules destabilize cIAP1 by activating auto-ubiquitylation[J]. J Biol Chem, 2008, 283(14):8961-8968.
[22] ITOH Y, ISHIKAWA M, NAITO M, et al. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins[J]. J Am Chem Soc, 2010, 132(16):5820-5826.
[23] BUCKLEY D L, GUSTAFSON J L, VAN MOLLE I, et al. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1alpha[J]. Angew Chem Int Ed Engl, 2012, 51(46):11463-11467.
[24] SOARES P, GADD M S, FROST J, et al. Group-based optimization of potent and cell-active inhibitors of the von hippel-lindau (VHL) E3 ubiquitin ligase: structure-activity relationships leading to the chemical probe (2S,4R)-1-((S)-2-(1-cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298)[J]. J Med Chem, 2018, 61(2):599-618.
[25] FISCHER E S, BOHM K, LYDEARD J R, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide[J]. Nature, 2014, 512(7512):49-53.
[26] LAI A C, TOURE M, HELLERSCHMIED D, et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL[J]. Angew Chem Int Ed Engl, 2016, 55(2):807-810.
[27] CHAN K H, ZENGERLE M, TESTA A, et al. Impact of target warhead and linkage vector on inducing protein degradation: comparison of bromodomain and extra-terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds[J]. J Med Chem, 2018, 61(2):504-513.
[28] HAN X, WANG C, QIN C, et al. Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer[J]. J Med Chem, 2019,62(2):941-964.
[29] GECHIJIAN L N, BUCKLEY D L, LAWLOR M A, et al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands[J]. Nat Chem Biol, 2018, 14(4):405-412.
[30] BONDESON D P, MARES A, SMITH I E, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs[J]. Nat Chem Biol, 2015, 11(8):611-617.
[31] BURSLEM G M, SMITH B E, LAI A C, et al. The advantages of targeted protein degradation over inhibition: an RTK case study[J]. Cell Chem Biol, 2018, 25(1):67-77.
[32] CROMM P M, SAMARASINGHE K T G, HINES J, et al. Addressing kinase-independent functions of fak via PROTAC-mediated degradation[J]. J Am Chem Soc, 2018, 140(49):17019-17026.
[33] BURSLEM G M, SONG J, CHEN X, et al. Enhancing antiproliferative activity and selectivity of a FLT-3 inhibitor by proteolysis targeting chimera conversion[J]. J Am Chem Soc, 2018, 140(48):16428-16432.
[34] NUNES J, MCGONAGLE G A, EDEN J, et al. Targeting IRAK4 for degradation with PROTACs[J]. ACS Med Chem Lett, 2019, 10(7):1081-1085.
[35] TOVELL H, TESTA A, ZHOU H, et al. Design and characterization of SGK3-PROTAC1, an isoform specific SGK3 kinase PROTAC degrader[J]. ACS Chem Biol, 2019,14(9):2024-2034.
[36] WANG X, FENG S, FAN J, et al. New strategy for renal fibrosis: targeting Smad3 proteins for ubiquitination and degradation[J]. Biochem Pharmacol, 2016, 116:200-209.
[37] CREW A P, RAINA K, DONG H, et al. Identification and characterization of von hippel-lindau-recruiting proteolysis targeting chimeras (PROTACs) of tank-binding kinase 1[J]. J Med Chem, 2018, 61(2):583-598.
[38] BURSLEM G M, SCHULTZ A R, BONDESON D P, et al. Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation[J]. Cancer Res, 2019, 79(18):4744-4753.
[39] FARNABY W, KOEGL M, ROY M J, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design[J]. Nat Chem Biol, 2019, 15(7):672-680.
[40] NOWAK R P, DEANGELO S L, BUCKLEY D, et al. Plasticity in binding confers selectivity in ligand-induced protein degradation[J]. Nat Chem Biol, 2018, 14(7):706-714.
[41] REMILLARD D, BUCKLEY D L, PAULK J, et al. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands[J]. Angewandte Chem, 2017, 56(21):5738-5743.
[42] SCHIEDEL M, HERP D, HAMMELMANN S, et al. Chemically induced degradation of sirtuin 2 (sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals)[J]. J Med Chem, 2018, 61(2):482-491.
[43] YANG K, SONG Y, XIE H, et al. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders[J]. Bioorg Med Chem Lett, 2018, 28(14):2493-2497.
[44] LI W, GAO C, ZHAO L, et al. Phthalimide conjugations for the degradation of oncogenic PI3K[J]. Eur J Med Chem, 2018, 151:237-247.
[45] MCCOULL W, CHEUNG T, ANDERSON E, et al. Development of a novel B-cell lymphoma 6 (BCL6) PROTAC to provide insight into small molecule targeting of BCL6[J]. ACS Chem Biol, 2018, 13(11):3131-3141.
[46] BIAN J, REN J, LI Y, et al. Discovery of wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity[J]. Bioorg Chem, 2018, 81:373-381.
[47] WINTER G E, BUCKLEY D L, PAULK J, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation[J]. Science, 2015, 348(6241):1376-1381.
[48] CIEŚLAK M, KAŹMIERCZAK-BARAŃSKA J, KRÓóLEWSKA-GOLIŃSKA K, et al. New thalidomide-resembling dicarboximides target ABC50 protein and show antileukemic and immunomodulatory activities[J]. Biomolecules, 2019, 9(9):446.
[49] SONG Y, PARK P M C, WU L, et al. Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma[J]. Leukemia, 2019, 33(11):2685-2694.
[50] OHOKA N, NAGAI K, HATTORI T, et al. Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway[J]. Cell Death Dis, 2014, 5(11):e1513.
[51] OKUHIRA K, OHOKA N, SAI K, et al. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein[J]. FEBS Lett, 2011, 585(8):1147-1152.
[52] ITOH Y, KITAGUCHI R, ISHIKAWA M, et al. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers[J]. Bioorg Med Chem, 2011, 19(22):6768-6778.
[53] ZHAO Q, LAN T, SU S, et al. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule[J]. Chem Commun (Camb), 2019, 55(3):369-372.
[54] SAKAMOTO K M, KIM K B, VERMA R, et al. Development of protacs to target cancer-promoting proteins for ubiquitination and degradation[J]. Mol Cell Proteomics, 2003, 2(12):1350-1358.
[55] WARD C C, KLEINMAN J I, BRITTAIN S M, et al. Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications[J]. ACS Chem Biol, 2019, 14(11):2430-2440.
[56] SPRADLIN J N, HU X, WARD C C, et al. Harnessing the anti-cancer natural product nimbolide for targeted protein degradation[J]. Nat Chem Biol, 2019, 15(7):747-755.
[57] ZHANG X, CROWLEY V M, WUCHERPFENNIG T G, et al. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16[J]. Nat Chem Biol, 2019, 15(7):737-746.
[58] SCHEEPSTRA M, HEKKING K F W, VAN HIJFTE L, et al. Bivalent ligands for protein degradation in drug discovery[J]. Comput Struct Biotechnol J, 2019, 17:160-176.
[59] MANIACI C, HUGHES S J, TESTA A, et al. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation[J]. Nature Commun, 2017, 8(1):830.
[60] TOMOSHIGE S, HASHIMOTO Y, ISHIKAWA M. Efficient protein knockdown of HaloTag-fused proteins using hybrid molecules consisting of IAP antagonist and HaloTag ligand[J]. Bioorg Med Chem, 2016, 24(14):3144-3148.
[61] TINWORTH C P, LITHGOW H, DITTUS L, et al. PROTAC-mediated degradation of Bruton′s tyrosine kinase is inhibited by covalent binding[J]. ACS Chem Biol, 2019, 14(3):342-347.
[62] CYRUS K, WEHENKEL M, CHOI E Y, et al. Impact of linker length on the activity of PROTACs[J]. Mol Biosyst, 2011, 7(2):359-364.
[63] CYRUS K, WEHENKEL M, CHOI E Y, et al. Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs[J]. Chem Med Chem, 2010, 5(7):979-985.
[64] GADD M S, TESTA A, LUCAS X, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation[J]. Nat Chem Biol, 2017, 13(5):514-521.
[65] RICHING K M, MAHAN S, CORONA C R, et al. Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action[J]. ACS Chem Biol, 2018, 13(9):2758-2770.
[66] XIA L, LIU W, SONG Y, et al. The present and future of novel protein degradation technology[J]. Curr Top Med Chem, 2019, 19(20):1784-1788.
[67] ZHANG L, RILEY-GILLIS B, VIJAY P, et al. Acquired resistance to bet-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes[J]. Mol Cancer Ther, 2019, 18(7):1302-1311.
[68] DOBROVOLSKY D, WANG E S, MORROW S, et al. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer[J]. Blood, 2019, 133(9):952-961.